Can HMG Co-A reductase inhibitors (“statins”) slow the progression of age-related macular degeneration? The Age-Related Maculopathy Statin Study (ARMSS)
Robyn H Guymer1,3, Peter N Dimitrov1, Mary Varsamidis1, Lyndell L Lim1,3, Paul N Baird1, Algis J Vingrys2, Luba Robman1,31Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia; 2Department of Optometry and Visual Sciences, University of Melbourne, Melbourne, Vict...
Guardado en:
Autores principales: | Robyn H Guymer, Peter N Dimitrov, Mary Varsamidis, Lyndell L Lim, Paul N Baird, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/69b5d9d75107474581c3803ae3124466 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol
por: Shi-You Jiang, et al.
Publicado: (2018) -
Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration.
por: Robyn H Guymer, et al.
Publicado: (2013) -
Statins and the progression of age-related macular degeneration in the United States.
por: Cassie A Ludwig, et al.
Publicado: (2021) -
Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
por: Takahashi H, et al.
Publicado: (2018) -
The controversy over the association between statins use and progression of age-related macular degeneration: a mini review
por: Vasileios Peponis, et al.
Publicado: (2010)